dichlormid: antidote for EPTC injury in corn; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 37829 |
| CHEMBL ID | 2251310 |
| CHEBI ID | 81956 |
| SCHEMBL ID | 117463 |
| MeSH ID | M0048740 |
| Synonym |
|---|
| 2,2-dichloro-n,n-di-2-propenylacetamide |
| compound r-25788 |
| dichlormid |
| r-25788 |
| stauffer r-25788 |
| brn 1768843 |
| n,n-diallyl-2,3-dichloroacetamide |
| n,n-diallyldichloroacetamide |
| acetamide, n,n-diallyl-2,2-dichloro- |
| einecs 253-658-8 |
| 37764-25-3 |
| acetamide, 2,2-dichloro-n,n-di-2-propenyl- |
| n,n-diallyl-2,2-dichloroacetamide |
| D3397 |
| 2,2-dichloro-n,n-bis(prop-2-enyl)acetamide |
| yrmlforxooijdr-uhfffaoysa- |
| inchi=1/c8h11cl2no/c1-3-5-11(6-4-2)8(12)7(9)10/h3-4,7h,1-2,5-6h2 |
| 2,2-dichloro-n,n-di(prop-2-enyl)acetamide |
| AKOS003254307 |
| C18782 |
| cas-37764-25-3 |
| tox21_303463 |
| dtxsid4027997 , |
| dtxcid007997 |
| NCGC00257385-01 |
| tox21_202064 |
| NCGC00259613-01 |
| 2,2-bis(chloranyl)-n,n-bis(prop-2-enyl)ethanamide |
| A823859 |
| hsdb 8428 |
| unii-e901j4382o |
| acetamide, 2,2-dichloro-n,n-di-2-propen-1-yl- |
| e901j4382o , |
| dichloromid |
| FT-0639405 |
| chebi:81956 , |
| CHEMBL2251310 |
| dichlormid [mi] |
| n,n-diallyl-.alpha.,.alpha.-dichloroacetamide |
| SCHEMBL117463 |
| n,n-diallyl dichloroacetamide |
| mfcd00072464 |
| dichloromide |
| dichlormid, pestanal(r), analytical standard |
| n,n-diallyldichloracetamide |
| Q3026531 |
| BS-16977 |
| AMY25662 |
| CS-W015238 |
| SY036270 |
| D90183 |
| HY-W014522 |
| Class | Description |
|---|---|
| tertiary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 64.0121 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 6.1131 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 22.9052 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 50.8466 | 0.0015 | 30.6073 | 15,848.9004 | AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 64.0121 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 21.8724 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 36.3022 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 16.0791 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.5705 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1100793 | Binding affinity to SafBP receptor in Zea mays (maize) seedlings by [3H]Saf(R-29148) binding assay | 2000 | Journal of agricultural and food chemistry, Mar, Volume: 48, Issue:3 | Comparative three-dimensional quantitative structure-activity relationship study of safeners and herbicides. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||